Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment completed in phase II colorectal cancer study of HGS-ETR1

Feb. 25, 2005

Update on the antitumor effects of autologous Xcellerated T-cells in hematological malignancies

Feb. 24, 2005

New phase I/II study of AP-12009

Feb. 24, 2005

Pharmexa files to start second phase II HER-2 Protein AutoVac study

Feb. 23, 2005

Pentrys prostate cancer study nearing completion of enrollment

Feb. 22, 2005

Long-lasting responses seen in mycosis fungoides patients receiving HuMax-CD4

Feb. 22, 2005

Good safety profile of MDX-010 in patients with relapsing malignancies after allo-HCT

Feb. 21, 2005

Evotec to provide process validation for AMD-3100

Feb. 18, 2005

Promising effects reported for 131I-labetuzumab in colorectal cancer patients with liver metastases

Feb. 17, 2005

Seattle Genetics and CuraGen expand antibody-drug conjugate collaboration

Feb. 17, 2005

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...